Use of biologicals as immunotherapy in asthma and related diseases

References

• Beeh KM, Ksoll M, Buhl R. Elevation of total serum immunoglobulin E is associated with asthma in nonallergic individuals. Eur. Respir. J.16, 609–614 (2000).
   PubMed Web of Science ®Google Scholar
• Burrows B, Martinez FD, Halonen M, Barbee RA, Cline MG. Association of asthma with serum IgE levels and skin-test reactivity to allergens. N. Engl. J. Med.320, 271–277 (1989).
   PubMed Web of Science ®Google Scholar
• Bousquet J, Vignola AM, Demoly P. Links between rhinitis and asthma. Allergy58, 691–706 (2003).
   PubMed Web of Science ®Google Scholar
• MacGlashan DW Jr, Bochner BS, Adelman DC, Jardieu PM, Togias A, Lichtenstein LM. Serum IgE level drives basophil and mast cell IgE receptor display. Int. Arch. Allergy Immunol.113, 45–47 (1997).
   PubMed Web of Science ®Google Scholar
• Arshad SH, Holgate S. The role of IgE in allergen-induced inflammation and the potential for intervention with a humanized monoclonal anti-IgE antibody. Clin. Exp. Allergy31, 1344–1351 (2001).
   PubMed Web of Science ®Google Scholar
• Strunk RC, Bloomberg GR. Omalizumab for asthma. N. Engl. J. Med.354, 2689–2695 (2006).
   PubMed Web of Science ®Google Scholar
• Schulman ES. Development of a monoclonal anti-immunoglobulin E antibody (omalizumab) for the treatment of allergic respiratory disorders. Am. J. Respir. Crit. Care Med.164, S6–S11 (2001).
   PubMed Web of Science ®Google Scholar
• Beck LA, Marcotte GV, MacGlashan D, Togias A, Saini S. Omalizumab-induced reductions in mast cell FcεRI expression and function. J. Allergy Clin. Immunol.114, 527–530 (2004).
   PubMed Web of Science ®Google Scholar
• Lin H, Boesel KM, Griffith DT et al. Omalizumab rapidly decreases nasal allergic response and FcεRI on basophils. J. Allergy Clin. Immunol.113, 297–302 (2004).
   PubMed Web of Science ®Google Scholar
• Prussin C, Griffith DT, Boesel KM, Lin H, Foster B, Casale TB. Omalizumab treatment downregulates dendritic cell FcεRI expression. J. Allergy Clin. Immunol.112, 1147–1154 (2003).
   PubMed Web of Science ®Google Scholar
• Boulet LP, Chapman KR, Cote J et al. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am. J. Respir. Crit. Care Med.155, 1835–1840 (1997).
   PubMed Web of Science ®Google Scholar
• Fahy JV, Fleming HE, Wong HH et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am. J. Respir. Crit. Care Med.155, 1828–1834 (1997).
   PubMed Web of Science ®Google Scholar
• Djukanovic R, Wilson SJ, Kraft M et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am. J. Respir. Crit. Care Med.170, 583–593 (2004).
   PubMed Web of Science ®Google Scholar
• Green RH, Brightling CE, McKenna S et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet360, 1715–1721 (2002).
   PubMed Web of Science ®Google Scholar
• Louis R, Lau LC, Bron AO, Roldaan AC, Radermecker M, Djukanovic R. The relationship between airways inflammation and asthma severity. Am. J. Respir. Crit. Care Med.161, 9–16 (2000).
   PubMed Web of Science ®Google Scholar
• Foster B, Metcalfe DD, Prussin C. Human dendritic cell 1 and dendritic cell 2 subsets express FcεRI: correlation with serum IgE and allergic asthma. J. Allergy Clin. Immunol.112, 1132–1138 (2003).
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma. Global Strategy for Asthma Management Program, National Institutes of Health, National Heart, Lung and Blood Institute. Revised. (2002).
   Google Scholar
• Humbert M, Beasley R, Ayres J et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy60, 309–316 (2005).
   PubMed Web of Science ®Google Scholar
• Ayres JG, Higgins B, Chilvers ER, Ayre G, Blogg M, Fox H. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy59, 701–708 (2004).
   PubMed Web of Science ®Google Scholar
• Busse W, Corren J, Lanier BQ et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J. Allergy Clin. Immunol.108, 184–190 (2001).
   PubMed Web of Science ®Google Scholar
• Holgate ST, Chuchalin AG, Hebert J et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma. Clin. Exp. Allergy34, 632–638 (2004).
   PubMed Web of Science ®Google Scholar
• Soler M, Matz J, Townley R et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur. Respir. J.18, 254–261 (2001).
   PubMed Web of Science ®Google Scholar
• Holgate S, Bousquet J, Wenzel S, Fox H, Liu J, Castellsague J. Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality. Curr. Med. Res. Opin.17, 233–240 (2001).
   PubMed Web of Science ®Google Scholar
• Buhl R, Soler M, Matz J et al. Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Eur. Respir. J.20, 73–78 (2002).
   PubMed Web of Science ®Google Scholar
• Lanier BQ, Corren J, Lumry W, Liu J, Fowler-Taylor A, Gupta N. Omalizumab is effective in the long-term control of severe allergic asthma. Ann. Allergy Asthma Immunol.91, 154–159 (2003).
   PubMed Web of Science ®Google Scholar
• Bousquet J, Cabrera P, Berkman N et al. The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma. Allergy60, 302–308 (2005).
   PubMed Web of Science ®Google Scholar
• Buhl R, Hanf G, Soler M et al. The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. Eur. Respir. J.20, 1088–1094 (2002).
   PubMed Web of Science ®Google Scholar
• Finn A, Gross G, van Bavel J et al. Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. J. Allergy Clin. Immunol.111, 278–284 (2003).
   PubMed Web of Science ®Google Scholar
• Bousquet J, Rabe K, Humbert M et al. Predicting and evaluating response to omalizumab in patients with severe allergic asthma. Respir. Med.101, 1483–1492 (2007).
   PubMed Web of Science ®Google Scholar
• Molimard M, de Blay F, Didier A, Le Gros V. Effectiveness of omalizumab (Xolair) in the first patients treated in real-life practice in France. Respir. Med.102, 71–76 (2008).
   PubMed Web of Science ®Google Scholar
• Deniz YM, Gupta N. Safety and tolerability of omalizumab (Xolair), a recombinant humanized monoclonal anti-IgE antibody. Clin. Rev. Allergy Immunol.29, 31–48 (2005).
   PubMed Web of Science ®Google Scholar
• Cox L, Platts-Mills TA, Finegold I, Schwartz LB, Simons FE, Wallace DV. American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force report on omalizumab-associated anaphylaxis. J. Allergy Clin. Immunol.120, 1373–1377 (2007).
   PubMed Web of Science ®Google Scholar
• Kriegler M, Perez C, DeFay K, Albert I, Lu SD. A novel form of TNF/cachectin is a cell surface cytotoxic transmembrane protein: ramifications for the complex physiology of TNF. Cell53, 45–53 (1988).
   PubMed Web of Science ®Google Scholar
• Smith RA, Baglioni C. The active form of tumor necrosis factor is a trimer. J. Biol. Chem.262, 6951–6954 (1987).
   PubMed Web of Science ®Google Scholar
• Brockhaus M, Schoenfeld HJ, Schlaeger EJ, Hunziker W, Lesslauer W, Loetscher H. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. Proc. Natl Acad. Sci. USA87, 3127–3131 (1990).
   PubMed Web of Science ®Google Scholar
• Medzhitov R, Janeway C Jr. Innate immunity. N. Engl. J. Med.343, 338–344 (2000).
   PubMed Web of Science ®Google Scholar
• Cazzola M, Polosa R. Anti-TNF-α and Th1 cytokine-directed therapies for the treatment of asthma. Curr. Opin. Allergy Clin. Immunol.6, 43–50 (2006).
   PubMed Web of Science ®Google Scholar
• Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. N. Engl. J. Med.344, 907–916 (2001).
   PubMed Web of Science ®Google Scholar
• Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N. Engl. J. Med.350, 2167–2179 (2004).
   PubMed Web of Science ®Google Scholar
• Ying S, Robinson DS, Varney V et al. TNF α mRNA expression in allergic inflammation. Clin. Exp. Allergy21, 745–750 (1991).
   PubMed Web of Science ®Google Scholar
• Bradding P, Roberts JA, Britten KM et al. Interleukin-4, -5, and -6 and tumor necrosis factor-α in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines. Am. J. Respir. Cell Mol. Biol.10, 471–480 (1994).
   PubMed Web of Science ®Google Scholar
• Thomas PS, Yates DH, Barnes PJ. Tumor necrosis factor-α increases airway responsiveness and sputum neutrophilia in normal human subjects. Am. J. Respir. Crit. Care Med.152, 76–80 (1995).
   PubMed Web of Science ®Google Scholar
• Adner M, Rose AC, Zhang Y et al. An assay to evaluate the long-term effects of inflammatory mediators on murine airway smooth muscle: evidence that TNFα up-regulates 5-HT2A-mediated contraction. Br. J. Pharmacol.137, 971–982 (2002).
   PubMed Web of Science ®Google Scholar
• Huber M, Beutler B, Keppler D. Tumor necrosis factor α stimulates leukotriene production in vivo. Eur. J. Immunol.18, 2085–2088 (1988).
   PubMed Web of Science ®Google Scholar
• van Overveld FJ, Jorens PG, Rampart M, de Backer W, Vermeire PA. Tumour necrosis factor stimulates human skin mast cells to release histamine and tryptase. Clin. Exp. Allergy21, 711–714 (1991).
   PubMed Web of Science ®Google Scholar
• Slungaard A, Vercellotti GM, Walker G, Nelson RD, Jacob HS. Tumor necrosis factor α/cachectin stimulates eosinophil oxidant production and toxicity towards human endothelium. J. Exp. Med.171, 2025–2041 (1990).
   PubMed Web of Science ®Google Scholar
• Scheurich P, Thoma B, Ucer U, Pfizenmaier K. Immunoregulatory activity of recombinant human tumor necrosis factor (TNF)-α: induction of TNF receptors on human T cells and TNF-α-mediated enhancement of T cell responses. J. Immunol.138, 1786–1790 (1987).
   PubMed Web of Science ®Google Scholar
• Lukacs NW, Strieter RM, Chensue SW, Widmer M, Kunkel SL. TNF-α mediates recruitment of neutrophils and eosinophils during airway inflammation. J. Immunol.154, 5411–5417 (1995).
   PubMed Web of Science ®Google Scholar
• Sullivan DE, Ferris M, Pociask D, Brody AR. Tumor necrosis factor-α induces transforming growth factor-β1 expression in lung fibroblasts through the extracellular signal-regulated kinase pathway. Am. J. Respir. Cell Mol. Biol.32, 342–349 (2005).
   PubMed Web of Science ®Google Scholar
• Howarth PH, Babu KS, Arshad HS et al. Tumour necrosis factor (TNFα) as a novel therapeutic target in symptomatic corticosteroid dependent asthma. Thorax60, 1012–1018 (2005).
   PubMed Web of Science ®Google Scholar
• Berry MA, Hargadon B, Shelley M et al. Evidence of a role of tumor necrosis factor α in refractory asthma. N. Engl. J. Med.354, 697–708 (2006).
   PubMed Web of Science ®Google Scholar
• Erin EM, Leaker BR, Nicholson GC et al. The effects of a monoclonal antibody directed against tumor necrosis factor-α in asthma. Am. J. Respir. Crit. Care Med.174, 753–762 (2006).
   PubMed Web of Science ®Google Scholar
• Brightling C, Berry M, Amrani Y. Targeting TNF-α: a novel therapeutic approach for asthma. J. Allergy Clin. Immunol.121, 5–10 (2008).
   PubMed Web of Science ®Google Scholar
• Morjaria JB, Chauhan AJ, Babu KS, Polosa R, Davies DE, Holgate ST. The role of a soluble TNF-α receptor fusion protein (etanercept) in corticosteroid-refractory asthma: a double blind, randomised placebo-controlled trial. Thorax63(7), 584–591 (2008).
   PubMed Web of Science ®Google Scholar
• Scheinfeld N. A comprehensive review and evaluation of the side effects of the tumor necrosis factor α blockers etanercept, infliximab and adalimumab. J. Dermatolog. Treat.15, 280–294 (2004).
   PubMedGoogle Scholar
• Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and anakinra therapies for rheumatoid arthritis: meta-analyses of randomized placebo-controlled trials. Ann. Rheum. Dis. DOI 10.1136/ard.2007.083188 (2008) (Epub ahead of print).
   Google Scholar
• Rennard SI, Fogarty C, Kelsen S et al. The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med.175, 926–934 (2007).
   PubMed Web of Science ®Google Scholar
• Desai SB, Furst DE. Problems encountered during anti-tumour necrosis factor therapy. Best Pract. Res. Clin. Rheumatol.20, 757–790 (2006).
   PubMed Web of Science ®Google Scholar
• Zeibecoglou K, Ying S, Yamada T et al. Increased mature and immature CCR3 messenger RNA+ eosinophils in bone marrow from patients with atopic asthma compared with atopic and nonatopic control subjects. J. Allergy Clin. Immunol.103, 99–106 (1999).
   PubMed Web of Science ®Google Scholar
• Robinson DS, Ying S, Bentley AM et al. Relationships among numbers of bronchoalveolar lavage cells expressing messenger ribonucleic acid for cytokines, asthma symptoms, and airway methacholine responsiveness in atopic asthma. J. Allergy Clin. Immunol.92, 397–403 (1993).
   PubMed Web of Science ®Google Scholar
• Chung KF, Barnes PJ. Cytokines in asthma. Thorax54, 825–857 (1999).
   PubMed Web of Science ®Google Scholar
• Tavernier J, Van der Heyden J, Verhee A et al. Interleukin 5 regulates the isoform expression of its own receptor α-subunit. Blood95, 1600–1607 (2000).
   PubMed Web of Science ®Google Scholar
• De Monchy JG, Kauffman HF, Venge P et al. Bronchoalveolar eosinophilia during allergen-induced late asthmatic reactions. Am. Rev. Respir. Dis.131, 373–376 (1985).
   PubMed Web of Science ®Google Scholar
• Beasley R, Roche WR, Roberts JA, Holgate ST. Cellular events in the bronchi in mild asthma and after bronchial provocation. Am. Rev. Respir. Dis.139, 806–817 (1989).
   PubMed Web of Science ®Google Scholar
• Shi HZ, Xiao CQ, Zhong D et al. Effect of inhaled interleukin-5 on airway hyperreactivity and eosinophilia in asthmatics. Am. J. Respir. Crit. Care Med.157, 204–209 (1998).
   PubMed Web of Science ®Google Scholar
• Corrigan CJ, Haczku A, Gemou-Engesaeth V et al. CD4 T-lymphocyte activation in asthma is accompanied by increased serum concentrations of interleukin-5. Effect of glucocorticoid therapy. Am. Rev. Respir. Dis.147, 540–547 (1993).
   PubMed Web of Science ®Google Scholar
• Humbert M, Corrigan CJ, Kimmitt P, Till SJ, Kay AB, Durham SR. Relationship between IL-4 and IL-5 mRNA expression and disease severity in atopic asthma. Am. J. Respir. Crit. Care Med.156, 704–708 (1997).
   PubMed Web of Science ®Google Scholar
• Yasruel Z, Humbert M, Kotsimbos TC et al. Membrane-bound and soluble α IL-5 receptor mRNA in the bronchial mucosa of atopic and nonatopic asthmatics. Am. J. Respir. Crit. Care Med.155, 1413–1418 (1997).
   PubMed Web of Science ®Google Scholar
• Rothenberg ME. Eosinophilia. N. Engl. J. Med.338, 1592–1600 (1998).
   PubMed Web of Science ®Google Scholar
• Kung TT, Stelts DM, Zurcher JA et al. Involvement of IL-5 in a murine model of allergic pulmonary inflammation: prophylactic and therapeutic effect of an anti-IL-5 antibody. Am. J. Respir. Cell Mol. Biol.13, 360–365 (1995).
   PubMed Web of Science ®Google Scholar
• Mauser PJ, Pitman A, Witt A et al. Inhibitory effect of the TRFK-5 anti-IL-5 antibody in a guinea pig model of asthma. Am. Rev. Respir. Dis.148, 1623–1627 (1993).
   PubMed Web of Science ®Google Scholar
• Mauser PJ, Pitman AM, Fernandez X et al. Effects of an antibody to interleukin-5 in a monkey model of asthma. Am. J. Respir. Crit. Care Med.152, 467–472 (1995).
   PubMed Web of Science ®Google Scholar
• Egan RW, Athwal D, Bodmer MW et al. Effect of SCH55700, a humanized monoclonal antibody to human interleukin-5, on eosinophilic responses and bronchial hyperreactivity. Arzneimittelforschung49, 779–790 (1999).
   PubMed Web of Science ®Google Scholar
• Kips JC, O’Connor BJ, Langley SJ et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am. J. Respir. Crit. Care Med.167, 1655–1659 (2003).
   PubMed Web of Science ®Google Scholar
• Leckie MJ, ten Brinke A, Khan J et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet356, 2144–2148 (2000).
   PubMed Web of Science ®Google Scholar
• O’Byrne PM, Inman MD, Parameswaran K. The trials and tribulations of IL-5, eosinophils, and allergic asthma. J. Allergy Clin. Immunol.108, 503–508 (2001).
   PubMed Web of Science ®Google Scholar
• Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil’s role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am. J. Respir. Crit. Care Med.167, 199–204 (2003).
   PubMed Web of Science ®Google Scholar
• Flood-Page P, Swenson C, Faiferman I et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am. J. Respir. Crit. Care Med.176, 1062–1071 (2007).
   PubMed Web of Science ®Google Scholar
• Ricci M. IL-4: a key cytokine in atopy. Clin. Exp. Allergy24, 801–812 (1994).
   PubMed Web of Science ®Google Scholar
• Pauwels RA, Brusselle GG, Tournoy KG, Lambrecht BN, Kips JC. Cytokines and their receptors as therapeutic targets in asthma. Clin. Exp. Allergy28(Suppl. 3), 1–5 (1998).
   Google Scholar
• Coyle AJ, Le Gros G, Bertrand C et al. Interleukin-4 is required for the induction of lung Th2 mucosal immunity. Am. J. Respir. Cell Mol. Biol.13, 54–59 (1995).
   PubMed Web of Science ®Google Scholar
• Parronchi P, Macchia D, Piccinni MP et al. Allergen- and bacterial antigen-specific T-cell clones established from atopic donors show a different profile of cytokine production. Proc. Natl Acad. Sci. USA88, 4538–4542 (1991).
   PubMed Web of Science ®Google Scholar
• Ricci M, Matucci A, Rossi O. IL-4 as a key factor influencing the development of allergen-specific Th2-like cells in atopic individuals. J. Investig. Allergol. Clin. Immunol.7, 144–150 (1997).
   PubMed Web of Science ®Google Scholar
• Garlisi CG, Kung TT, Wang P et al. Effects of chronic anti-interleukin-5 monoclonal antibody treatment in a murine model of pulmonary inflammation. Am. J. Respir. Cell Mol. Biol.20, 248–255 (1999).
   PubMed Web of Science ®Google Scholar
• Hart TK, Blackburn MN, Brigham-Burke M et al. Preclinical efficacy and safety of pascolizumab (SB240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma. Clin. Exp. Immunol.130, 93–100 (2002).
   PubMed Web of Science ®Google Scholar
• Caramori G, Groneberg D, Ito K, Casolari P, Adcock IM, Papi A. New drugs targeting Th2 lymphocytes in asthma. J. Occup. Med. Toxicol.3(Suppl. 1), S6 (2008).
   PubMedGoogle Scholar
• Borish LC, Nelson HS, Lanz MJ et al. Interleukin-4 receptor in moderate atopic asthma. A Phase I/II randomized, placebo-controlled trial. Am. J. Respir. Crit. Care Med.160, 1816–1823 (1999).
   PubMed Web of Science ®Google Scholar
• Borish LC, Nelson HS, Corren J et al. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J. Allergy Clin. Immunol.107, 963–970 (2001).
   PubMed Web of Science ®Google Scholar
• Wenzel S, Wilbraham D, Fuller R, Getz EB, Longphre M. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two Phase 2a studies. Lancet370, 1422–1431 (2007).
   PubMed Web of Science ®Google Scholar
• Holgate ST, Polosa R. Treatment strategies for allergy and asthma. Nat. Rev. Immunol.8, 218–230 (2008).
   PubMed Web of Science ®Google Scholar
• Wills-Karp M. Interleukin-13 in asthma pathogenesis. Immunol. Rev.202, 175–190 (2004).
   PubMed Web of Science ®Google Scholar
• Wynn TA. IL-13 effector functions. Annu. Rev. Immunol.21, 425–456 (2003).
   PubMed Web of Science ®Google Scholar
• Zurawski G, de Vries JE. Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells. Immunol. Today15, 19–26 (1994).
   PubMedGoogle Scholar
• Aman MJ, Tayebi N, Obiri NI, Puri RK, Modi WS, Leonard WJ. cDNA cloning and characterization of the human interleukin 13 receptor α chain. J. Biol. Chem.271, 29265–29270 (1996).
   PubMed Web of Science ®Google Scholar
• Callard RE, Matthews DJ, Hibbert L. IL-4 and IL-13 receptors: are they one and the same? Immunol. Today17, 108–110 (1996).
   PubMedGoogle Scholar
• Wills-Karp M, Luyimbazi J, Xu X et al. Interleukin-13: central mediator of allergic asthma. Science282, 2258–2261 (1998).
   PubMed Web of Science ®Google Scholar
• Grunig G, Warnock M, Wakil AE et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science282, 2261–2263 (1998).
   PubMed Web of Science ®Google Scholar
• Kuperman DA, Huang X, Koth LL et al. Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma. Nat. Med.8, 885–889 (2002).
   PubMed Web of Science ®Google Scholar
• Zhu Z, Homer RJ, Wang Z et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J. Clin. Invest.103, 779–788 (1999).
   PubMed Web of Science ®Google Scholar
• Fallon PG, Emson CL, Smith P, McKenzie AN. IL-13 overexpression predisposes to anaphylaxis following antigen sensitization. J. Immunol.166, 2712–2716 (2001).
   PubMed Web of Science ®Google Scholar
• Berry MA, Parker D, Neale N et al. Sputum and bronchial submucosal IL-13 expression in asthma and eosinophilic bronchitis. J. Allergy Clin. Immunol.114, 1106–1109 (2004).
   PubMed Web of Science ®Google Scholar
• Noah TL, Tudor GE, Ivins SS, Murphy PC, Peden DB, Henderson FW. Repeated measurement of nasal lavage fluid chemokines in school-age children with asthma. Ann. Allergy Asthma Immunol.96, 304–310 (2006).
   PubMed Web of Science ®Google Scholar
• Prieto J, Lensmar C, Roquet A et al. Increased interleukin-13 mRNA expression in bronchoalveolar lavage cells of atopic patients with mild asthma after repeated low-dose allergen provocations. Respir. Med.94, 806–814 (2000).
   PubMed Web of Science ®Google Scholar
• Batra V, Musani AI, Hastie AT et al. Bronchoalveolar lavage fluid concentrations of transforming growth factor (TGF)-β1, TGF-β2, interleukin (IL)-4 and IL-13 after segmental allergen challenge and their effects on α-smooth muscle actin and collagen III synthesis by primary human lung fibroblasts. Clin. Exp. Allergy34, 437–444 (2004).
   PubMed Web of Science ®Google Scholar
• Postma DS, Meyers DA, Jongepier H, Howard TD, Koppelman GH, Bleecker ER. Genomewide screen for pulmonary function in 200 families ascertained for asthma. Am. J. Respir. Crit. Care Med.172, 446–452 (2005).
   PubMed Web of Science ®Google Scholar
• Noguchi E, Shibasaki M, Arinami T et al. Evidence for linkage between asthma/atopy in childhood and chromosome 5q31–q33 in a Japanese population. Am. J. Respir. Crit. Care Med.156, 1390–1393 (1997).
   PubMed Web of Science ®Google Scholar
• Ober C, Cox NJ, Abney M et al. Genome-wide search for asthma susceptibility loci in a founder population. The Collaborative Study on the genetics of asthma. Hum. Mol. Genet.7, 1393–1398 (1998).
   PubMed Web of Science ®Google Scholar
• Zhang J, Pare PD, Sandford AJ. Recent advances in asthma genetics. Respir. Res.9, 4 (2008).
   PubMed Web of Science ®Google Scholar
• Hoffjan S, Nicolae D, Ober C. Association studies for asthma and atopic diseases: a comprehensive review of the literature. Respir. Res.4, 14 (2003).
   PubMed Web of Science ®Google Scholar
• Blanchard C, Mishra A, Saito-Akei H, Monk P, Anderson I, Rothenberg ME. Inhibition of human interleukin-13-induced respiratory and oesophageal inflammation by anti-human-interleukin-13 antibody (CAT-354). Clin. Exp. Allergy35, 1096–1103 (2005).
   PubMed Web of Science ®Google Scholar
• Renauld JC, Goethals A, Houssiau F, Merz H, Van Roost E, Van Snick J. Human P40/IL-9. Expression in activated CD4+ T cells, genomic organization, and comparison with the mouse gene. J. Immunol.144, 4235–4241 (1990).
   PubMed Web of Science ®Google Scholar
• Monteyne P, Renauld JC, Van Broeck J, Dunne DW, Brombacher F, Coutelier JP. IL-4-independent regulation of in vivo IL-9 expression. J. Immunol.159, 2616–2623 (1997).
   PubMed Web of Science ®Google Scholar
• Shimbara A, Christodoulopoulos P, Soussi-Gounni A et al. IL-9 and its receptor in allergic and nonallergic lung disease: increased expression in asthma. J. Allergy Clin. Immunol.105, 108–115 (2000).
   PubMed Web of Science ®Google Scholar
• Hultner L, Druez C, Moeller J et al. Mast cell growth-enhancing activity (MEA) is structurally related and functionally identical to the novel mouse T cell growth factor P40/TCGFIII (interleukin 9). Eur. J. Immunol.20, 1413–1416 (1990).
   PubMed Web of Science ®Google Scholar
• Doull IJ, Lawrence S, Watson M et al. Allelic association of gene markers on chromosomes 5q and 11q with atopy and bronchial hyperresponsiveness. Am. J. Respir. Crit. Care Med.153, 1280–1284 (1996).
   PubMed Web of Science ®Google Scholar
• Nicolaides NC, Holroyd KJ, Ewart SL et al. Interleukin 9: a candidate gene for asthma. Proc. Natl Acad. Sci. USA94, 13175–13180 (1997).
   PubMed Web of Science ®Google Scholar
• Levitt RC, McLane MP, MacDonald D et al. IL-9 pathway in asthma: new therapeutic targets for allergic inflammatory disorders. J. Allergy Clin. Immunol.103, S485–S491 (1999).
   PubMed Web of Science ®Google Scholar
• Cheng G, Arima M, Honda K et al. Anti-interleukin-9 antibody treatment inhibits airway inflammation and hyperreactivity in mouse asthma model. Am. J. Respir. Crit. Care Med.166, 409–416 (2002).
   PubMed Web of Science ®Google Scholar
• Kim JT, Kim CK, Koh YY. Serum levels of soluble interleukin-2 receptor at acute asthma exacerbation: relationship with severity of exacerbation and bronchodilator response. Int. Arch. Allergy Immunol.117, 263–269 (1998).
   PubMed Web of Science ®Google Scholar
• Busse W, Baker. J, Charous. B et al. Preliminary safety and efficacy of daclizumab in the treatment of patients with moderate to severe chronic persistent asthma. J. Allergy Clin. Immunol.113, S286 (2004).
   Google Scholar
• Bateman ED, Hurd SS, Barnes PJ et al. Global strategy for asthma management and prevention: GINA executive summary. Eur. Respir. J.31, 143–178 (2008).
   PubMed Web of Science ®Google Scholar
• Expert Panel Report 3 (EPR-3): guidelines for the diagnosis and management of asthma – summary report 2007. J. Allergy Clin. Immunol.120, S94–S138 (2007).
   PubMed Web of Science ®Google Scholar